In addition, the Company announced that it will host "The Future of Food” event, an exclusive culinary experience led by ...

LTIMindtree has implemented a new appraisal system for middle and senior-level managers that ties salary hikes to competency ...

HYDERABAD: VeGen Labs LLP, a biotech startup incubated at ASPIRE-TBI and ASPIRE-BioNEST, University of Hyderabad (UoH), has been awarded Rs 3.765 crore funding ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...

Stock market regulator Securities and Exchange Board of India's Chairman Tuhin Kanta Pandey, on his first full working day on ...

"It's heartening to see the chairman address employees on his first full day, discussing concerns about targets and KRAs," ...

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...

PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...

BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...

The BIRAC funding will enable comprehensive toxicology assessments, a necessary step in preparing for IND submission with ...